Supplementary Table 1: Change in CD4+ cell count in trials comparing rilpivirine-(RPV)-based regimens with other antiretroviral therapies (ART).
Study |
RPV group |
Comparator [p value*] |
Treatment-naïve patients |
||
TMC278-C204 Pozniak 2010 [33] |
48-week (RPV 25 mg/day arm) Change from BL (cells/µL), mean (SE), median 122.1 (11.8), 108 96-week (RPV 25 mg/day arm) Change from BL (cells/µL), mean (SE), median 145.8 (12.1), 138 |
48-week (RPV 25 mg/day arm) Change from BL (cells/µL), mean (SE), median 126.5 (11.1), 120.5 96-week Change from BL (cells/µL), mean (SE), median 159.8 (13.4), 170.5 |
ECHO & THRIVE Cohen 2012 [36] (ECHO & THRIVE week 48 results) Cohen 2013 [5] (ECHO & THRIVE week 96 results) |
48-week Change from BL (cells/mm3), mean (95% CI) 192 (181-203) 96-week Change from BL (cells/µL), mean (95% CI) 228 (215-240) |
48-week Change from BL (cells/mm3), mean (95% CI) 176 (165-188) 96-week Change from BL (cells/µL), mean (95% CI) 219 (206-233) |
STAR Cohen 2014 [32] (week 48 results) Van Lunzen 2016 [7] (week 96 results) |
48-week Change from BL (cells/µL), mean (SD) 200 (159) 96-week Change from BL (cells/µL), mean (SD) 178 (189) |
48-week Change from BL (cells/µL), mean (SD) 191 (144) 96-week Change from BL (cells/µL), mean (SD) 259 (191) |
Treatment-experienced, virologically controlled patients |
||
SPIRIT Palella 2014 [10] |
48-week Change from BL (cells/µL), mean 10 |
48 week Change from BL (~ 24 weeks BL ART & 24 weeks RPV + FTC + TDF) (cells/µL), mean -7 |
LATTE Margolis 2015 [28] |
48-week: 24-week induction (no RPV) + 24-week RPV Change from BL° (cells/µL), median (q1, q3) 219 (141, 343) 72-week: 24-week induction (no RPV) + 48-week RPV Change from BL° (cells/µL), median (q1, q3) 205 (117, 339) 96-week: 24-week induction (no RPV) + 72-week RPV Change from BL° (cells/µL), median (q1, q3) 259.5 (137, 355) |
24-week induction (no RPV) + 24-week RPV Change from BL° (cells/µL), median (q1, q3) 216 (133.5, 363) 72 week: 24-week induction (no RPV) + 48-week RPV Change from BL° (cells/µL), median (q1, q3) 208.5 (94, 355) 96 week: 24-week induction (no RPV) + 72-week RPV Change from BL° (cells/µL), median (q1, q3) 289 (158, 415) |
Probe Maggiolo 2016 [11] |
48-week Change from BL (cells/µL), mean (SD) 15 (184) |
48-week Change from BL (cells/µL), mean (SD) 16 (142) |
GS-US-366-1160 DeJesus 2017 [34] (week 48 results) Hagins 2018 [12] (week 96 results) |
48-week Change from BL (cells/µL), mean (SD) 23 (156) 96-week Change from BL (cells/µL), mean (SD) 12 (199.8) |
48-week Change from BL (cells/µL), mean (SD) 12 (153) [p = 0.31] 96-week Change from BL (cells/µL), mean (SD) 6 (153.2) [p = 0.64] |
SWORD-1 & SWORD-2 Llibre 2018 [9] (week 48 results) Aboud 2019 [8] (week 100 results) |
48-week Change from BL (cells/µL), median (q1, q3) 28 (-55, 112.5) 100-week Change from BL (cells/µL), median (q1, q3) 33 (-51, 148) |
48-week Change from BL (cells/µL), median (q1, q3) 22 (-46, 108) 100-week Change from the late-switch BL (~ 48 week of RPV + DTG) (cells/µL), median (q1, q3) 13 (-78, 98) |
SALIF Munderi, et al. 2019 [13] |
48-week Change from BL (cells/mm3), mean (SD) 26.2 (125.1) |
48-week Change from BL (cells/mm3), mean (SD) 6.1 (140.1) |
Petchkum 2019 [14] |
48-week BL - week 48 (cells/mm3), median (q1, q3) 563 (457, 727) - 547 (417, 708) |
48-week BL - week 48 (cells/mm3), median (q1, q3) 552 (434, 733) [p = 0.912] - 520 (424, 720) [p = 0.911] |
Abbreviations: BL: Baseline; DTG: Dolutegravir; RPV: Rilpivirine.
*for comparison with the RPV group, as reported in the publication.
°at study baseline, patients were treatment-naïve.